Acromegaly and other disorders of growth hormone secretion. Combined clinical staff conference at the National Institutes of Health.
Explore the source record for details and available documents.
SEARCH · PubMed Health
Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The results of stomatological examinations covering 16 children with osteogenesis imperfecta are reported. This disease is accompanied by typical symptoms in the oro-facial region. Dentinogenesis imperfecta occurred in 5 patients and can be considered an optional symptom of osteogenesis imperfecta.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The suppressive effect of two types of human interferon (fibroblast and leukocyte types) on bone marrow and peripheral blood erythroid colony formation by cells from patients with various disorders of erythropoiesis was studied. Bone marrow or peripheral blood mononuclear cells were isolated and cultured in plasma clots with Epo, and benzidine-positive erythroid colonies counted after 7 to 14 days' incubation. Specimens included cells from patients with thalassemia, sickle cell anemia, secondary polycythemia, nutritional anemia, hemolytic anemia, refractory anemia, and normal controls. Results show that with the exception of nutritional anemia cells, erythroid colony formation by all specimens was significantly inhibited (84% to 100%) by 100 to 200 U of either interferon type per milliliter. Erythroid colony formation by nutritional anemia bone marrow cells ws inhibited only 30% to 40% by 200 U/ml fibroblast or leukocyte interferon, and 100 U/ml were ineffective. Sickle cell peripheral blood mononuclear cells and refractory anemia bone marrow demonstrated marked inhibition of colony formation (86% to 97%) with 50 U/ml fibroblast or leukocyte interferon. Inhibition of colony formation by sickle cell peripheral blood mononuclear cells was completely abolished by addition of anti-interferon. Colony formation by refractory anemia bone marrow was inhibited 46% to 51% by as little as 10 U/ml fibroblast or leukocyte interferon. This concentration of interferon was ineffective with cells from thalassemia, secondary polycythemia, nutritional anemia, hemolytic anemia, and controls. Mouse bone marrow colony formation was not suppressed by 200 U/ml leukocyte interferon. These results demonstrate that fibroblast or leukocyte interferons inhibit in vitro erythroid colony formation by human bone marrow or peripheral blood mononuclear cells, the effect is abolished by anti-interferon, and inhibition may be species-specific. These studies reveal that cells obtained from certan patients are particularly sensitive to the cytoxic effects of interferon, and it may be useful to monitor the erythropoietic state of the patient during interferon chemotherapy.
Explore the source record for details and available documents.
Mulibrey nanism is a rare growth disorder of prenatal onset caused by mutations in the TRIM37 gene, which encodes a RING-B-box-coiled-coil protein. The pathogenetic mechanisms of mulibrey nanism are unknown. We have used transiently transfected cells and antibodies raised against the predicted TRIM37 protein to characterize the TRIM37 gene product and to determine its intracellular localization. We show that the human TRIM37 cDNA encodes a peroxisomal protein with an apparent molecular weight of 130 kD. Peroxisomal localization is compromised in mutant protein representing the major Finnish TRIM37 mutation but is retained in the protein representing the minor Finnish mutation. Colocalization of endogenous TRIM37 with peroxisomal markers was observed by double immunofluorescence staining in HepG2 and human intestinal smooth muscle cell lines. In human tissue sections, TRIM37 shows a granular cytoplasmic pattern. Endogenous TRIM37 is not imported into peroxisomes in peroxin 1 (PEX1(-/-)) and peroxin 5 (PEX5(-/-)) mutant fibroblasts but is imported normally in peroxin 7 (PEX7(-/-)) deficient fibroblasts, giving further evidence for a peroxisomal localization of TRIM37. Fibroblasts derived from patients with mulibrey nanism lack C-terminal TRIM37 immunoreactivity but stain normally for both peroxisomal matrix and membrane markers, suggesting apparently normal peroxisome biogenesis in patient fibroblasts. Taken together, this molecular evidence unequivocally indicates that TRIM37 is located in the peroxisomes, and Mulibrey nanism thus can be classified as a new peroxisomal disorder.